What Is Melanotan-2 Peptide? (Tanning & Beyond)

What Is Melanotan-2 Peptide? (Tanning & Beyond)

Melanotan-2 peptide (often abbreviated MT-2) is one of the most widely discussed research compounds in peptide science. And one of the most misunderstood. Unlike topical tanning accelerators or photosensitisers, Melanotan-2 peptide works at the receptor level, binding to melanocortin-1 (MC1R) receptors on melanocytes to directly stimulate melanin synthesis. This means tanning happens without UV exposure. A mechanism that sparked decades of research into photoprotection, photocarcinogenesis prevention, and potential applications far beyond cosmetic pigmentation. Most people encounter Melanotan-2 peptide in contexts related to tanning, but the compound's pharmacology touches appetite regulation, erectile function, and inflammatory pathways as well.

Our team at Real Peptides has synthesised and supplied research-grade Melanotan-2 peptide for laboratory use across institutions studying melanocortin receptor pharmacology. The gap between what the compound actually does and what casual overviews suggest is significant.

What is Melanotan-2 peptide, and how does it work at a cellular level?

Melanotan-2 peptide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), designed to bind melanocortin receptors. Primarily MC1R, MC3R, and MC4R. With higher affinity and longer half-life than the endogenous hormone. When MT-2 binds MC1R on melanocytes, it activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels, which in turn upregulates tyrosinase activity. The rate-limiting enzyme in melanin biosynthesis. The result is eumelanin production (the darker, more photoprotective form of melanin) without requiring UV-induced DNA damage to trigger the melanogenic cascade. Half-life is approximately 33 minutes after subcutaneous injection, but receptor occupancy persists longer, producing sustained pigmentation over multiple days.

The Melanocortin Receptor System Melanotan-2 Peptide Targets

Melanotan-2 peptide is a non-selective melanocortin receptor agonist, meaning it binds multiple receptor subtypes in the melanocortin family. Not just MC1R. MC1R drives melanogenesis in skin and hair follicles, but MC3R and MC4R are expressed in the hypothalamus and regulate energy homeostasis, feeding behaviour, and sexual function. This multi-receptor activity explains why users of Melanotan-2 peptide report effects beyond skin darkening: appetite suppression (via MC4R activation) and spontaneous erections (via MC3R/MC4R pathways) are documented in both preclinical models and human anecdotal reports. The compound's ability to cross-activate these receptors is what differentiates it from narrower MC1R-selective analogs developed later in research pipelines.

The original synthesis of Melanotan-2 peptide at the University of Arizona in the 1990s was part of a melanoma prevention strategy. Researchers hypothesised that artificially elevating melanin levels might reduce UV-induced DNA damage in high-risk populations. While that clinical development pathway stalled, the compound's receptor pharmacology continues to inform research on obesity, sexual dysfunction, and inflammatory skin conditions. Binding affinity studies show MT-2 has approximately 1,000-fold greater potency at MC1R than the endogenous α-MSH it mimics, which is why even low doses (typically 0.25–1mg per injection in research protocols) produce observable pigmentation.

How Melanotan-2 Peptide Differs from Natural Tanning Mechanisms

Natural tanning is a DNA-damage response. UV radiation. Specifically UVB wavelengths between 280–315nm. Penetrates the epidermis and induces cyclobutane pyrimidine dimers (CPDs) in keratinocyte DNA. These lesions trigger p53 activation, which upregulates proopiomelanocortin (POMC) expression in keratinocytes. POMC is cleaved into α-MSH, which then binds MC1R on melanocytes to initiate melanin synthesis. Melanotan-2 peptide bypasses the entire UV-DNA-damage cascade by directly occupying MC1R, delivering the melanogenic signal without photodamage. This is not photoprotection in the sense of preventing UV absorption. Melanin produced via Melanotan-2 peptide does offer some UV shielding (estimated SPF equivalent of 2–4 at peak pigmentation), but it does not undo or prevent CPD formation if UV exposure occurs afterward.

The timeline is also compressed. Natural tanning takes 48–72 hours post-UV exposure for visible pigmentation because the keratinocyte-to-melanocyte signalling pathway has lag time. Melanotan-2 peptide produces visible darkening within 24–48 hours of the first dose, and pigmentation deepens cumulatively with repeat dosing over 7–14 days. The tan persists longer than a UV-induced tan because receptor occupancy and elevated tyrosinase activity continue beyond the half-life of the peptide itself. Melanin remains in keratinocytes as they migrate to the stratum corneum, typically shedding over 3–4 weeks.

Melanotan-2 Peptide Dosing Protocols in Research Settings

Research protocols using Melanotan-2 peptide typically follow a loading phase followed by maintenance dosing. Loading doses range from 0.25mg to 1mg per day via subcutaneous injection, administered until desired pigmentation is achieved. Usually 7–14 days depending on baseline skin phototype. Maintenance dosing reduces frequency to 0.25–0.5mg once or twice weekly to sustain pigmentation without cumulative receptor overstimulation. The peptide is supplied as lyophilised powder and must be reconstituted with bacteriostatic water before injection. Stability after reconstitution is approximately 30 days when refrigerated at 2–8°C. Unreconstituted vials are stable at −20°C for extended periods.

Adverse effects documented in early-phase human trials include transient nausea (likely MC4R-mediated), facial flushing, and spontaneous erections in male subjects (MC3R/MC4R activation). These effects peak within 1–2 hours post-injection and resolve within 4–6 hours. Darker skin phototypes (Fitzpatrick IV–VI) show blunted pigmentation response compared to lighter phototypes (I–III), likely due to constitutively higher baseline melanin and receptor desensitisation. No serious adverse events were reported in Phase I trials, but clinical development was halted before reaching Phase III endpoints.

Melanotan-2 Peptide: Tanning vs Off-Target Receptor Activity Comparison

MC1R (Melanocytes)

Melanogenesis (pigmentation)

Upregulates tyrosinase via cAMP elevation

Skin darkening without UV exposure

This is the intended pharmacological target. Produces cosmetic tanning outcome

MC3R (Hypothalamus)

Neuromodulation, appetite, arousal

Alters neuropeptide signalling in central pathways

Mild appetite suppression, increased arousal

Off-target but dose-dependent. Becomes prominent above 0.5mg per injection

MC4R (Hypothalamus)

Energy homeostasis, feeding behaviour

Reduces orexigenic (hunger-stimulating) signalling

Appetite suppression, spontaneous erections

Documented in male subjects. Most pronounced side effect in clinical trials

MC5R (Exocrine Glands)

Sebum production regulation

Modulates sebocyte lipid synthesis

Variable effect on skin oiliness

Least understood MT-2 target. Minimal data from human studies

Key Takeaways

Melanotan-2 peptide is a synthetic cyclic heptapeptide analog of α-MSH, binding melanocortin receptors (MC1R, MC3R, MC4R) with approximately 1,000-fold greater potency than endogenous hormone.

It stimulates melanin production by activating adenylyl cyclase in melanocytes, raising cAMP levels and upregulating tyrosinase. The rate-limiting enzyme in melanogenesis.

Unlike UV-induced tanning, Melanotan-2 peptide produces pigmentation without DNA-damaging photon exposure, bypassing the keratinocyte CPD-damage cascade entirely.

Typical research dosing follows a loading phase (0.25–1mg daily for 7–14 days) followed by maintenance dosing (0.25–0.5mg once or twice weekly).

Off-target MC4R activation causes appetite suppression and spontaneous erections in male subjects. Effects that peak 1–2 hours post-injection and resolve within 4–6 hours.

The peptide must be stored as lyophilised powder at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 30 days.

What If: Melanotan-2 Peptide Scenarios

What If I Have Very Fair Skin (Fitzpatrick Type I) — Will Melanotan-2 Peptide Work?

Yes, but response varies. Fitzpatrick Type I skin has low constitutive melanin and limited melanocyte density, so Melanotan-2 peptide will produce pigmentation. But the shade achieved will be lighter and develop more slowly than in Type III or IV skin. Expect tan development over 10–14 days rather than 5–7 days. The compound cannot synthesise melanin in melanocytes that don't exist, so individuals with complete albinism (OCA1A, total absence of functional tyrosinase) will not tan regardless of dose.

What If I Stop Using Melanotan-2 Peptide — How Quickly Does the Tan Fade?

Pigmentation persists for 3–4 weeks after the last dose because melanin remains in keratinocytes as they migrate through the epidermis to the stratum corneum. Once receptor stimulation stops, no new melanin is synthesised, and the tan fades at the rate of natural epidermal turnover. Approximately 28 days. Maintenance dosing (0.25–0.5mg once or twice weekly) can sustain pigmentation indefinitely without cumulative receptor desensitisation.

What If I Experience Nausea After Injecting Melanotan-2 Peptide?

Nausea is MC4R-mediated and occurs in approximately 30–40% of users during initial doses. It peaks 30–60 minutes post-injection and resolves within 2–4 hours. Mitigation strategies: inject in the evening before sleep (so nausea occurs during rest), reduce dose to 0.1–0.25mg and titrate upward slowly, or take the injection with a small amount of food. The effect diminishes with repeated dosing as receptor adaptation occurs. Most users report nausea resolution by day 5–7 of a loading protocol.

The Unvarnished Truth About Melanotan-2 Peptide

Here's the honest answer: Melanotan-2 peptide works. But it is not FDA-approved for human use, and it never completed Phase III clinical trials. The compound was abandoned by its original developer (Clinuvel Pharmaceuticals) in favour of a narrower MC1R-selective analog (afamelanotide, marketed as Scenesse for erythropoietic protoporphyria). The reason: off-target MC3R/MC4R activity produced side effects (nausea, spontaneous erections, blood pressure changes) that regulatory bodies deemed unacceptable for a cosmetic indication. Melanotan-2 peptide remains available through research peptide suppliers and underground markets, but it is not a pharmaceutical-grade drug product. If you're exploring Melanotan-2 peptide for research purposes, source it from a supplier with third-party purity verification and understand that receptor cross-reactivity is inherent to the compound's structure. It is not a selective MC1R agonist.

Melanocortin Receptor Research Beyond Tanning

Melanotan-2 peptide's pharmacology extends far beyond cosmetic pigmentation. MC4R activation in the hypothalamus reduces food intake and increases energy expenditure, making melanocortin agonists a target for obesity research. Setmelanotide, an MC4R-selective agonist, received FDA approval in 2020 for rare genetic obesity disorders (POMC or LEPR deficiency). MC3R pathways are implicated in sexual arousal and erectile function. Bremelanotide (a derivative of Melanotan-2 peptide) was approved by the FDA in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in women. The melanocortin system also modulates inflammatory responses: MC1R activation on immune cells (macrophages, dendritic cells) suppresses pro-inflammatory cytokine release, which is why MC1R agonists are being studied for inflammatory skin conditions like vitiligo and atopic dermatitis.

Our experience at Real Peptides has shown consistent interest from research institutions studying melanocortin receptor pharmacology across these domains. The peptides we supply. Including compounds like P21 for neurogenesis research and Cerebrolysin for neuroprotection studies. Are synthesised to the same purity standards as our Melanotan-2 peptide batches. Every lot undergoes HPLC verification to confirm amino-acid sequencing accuracy and >98% purity before release.

If the melanocortin receptor system is central to your research question, Melanotan-2 peptide is one of several tools worth considering. The non-selectivity that disqualified it from cosmetic drug approval makes it valuable for multi-receptor pharmacology studies. Just understand that off-target activity is a feature, not a flaw, of its design. Research-grade peptides require proper handling: store lyophilised powder at −20°C, reconstitute with bacteriostatic water under sterile conditions, and refrigerate reconstituted solution at 2–8°C for use within 30 days. Temperature excursions above 25°C or freeze-thaw cycles degrade peptide bonds irreversibly. There is no visual indicator of degradation, so protocol adherence is critical.

Melanotan-2 peptide occupies a unique position in peptide research: it is one of the earliest synthetic melanocortin analogs, it demonstrated proof-of-concept for UV-independent melanogenesis, and its clinical failure redirected an entire research field toward receptor-selective compounds. If your work involves MC1R, MC3R, or MC4R pathways, the compound's well-documented receptor binding profile and decades of published preclinical data make it a reference standard. Source it from suppliers who provide certificate-of-analysis documentation for every batch. Purity matters when receptor affinity is the outcome measure.

Frequently Asked Questions

Melanotan-2 peptide binds melanocortin-1 receptors (MC1R) on melanocytes, activating adenylyl cyclase and raising intracellular cAMP levels. This upregulates tyrosinase, the enzyme that converts L-tyrosine into melanin. The process bypasses the UV-induced DNA damage that normally triggers melanin synthesis in natural tanning, delivering the melanogenic signal directly at the receptor level. Visible pigmentation appears within 24–48 hours of the first injection and deepens with repeat dosing over 7–14 days.

Melanotan-1 (afamelanotide) is a linear 13-amino-acid peptide selective for MC1R, producing tanning with minimal off-target effects. Melanotan-2 peptide is a cyclic 7-amino-acid analog that binds MC1R, MC3R, and MC4R non-selectively, causing appetite suppression and erectile effects in addition to tanning. Melanotan-1 received FDA approval for erythropoietic protoporphyria under the brand name Scenesse; Melanotan-2 peptide never completed Phase III trials and is not FDA-approved for any indication.

No. Melanotan-2 peptide produces melanin, which offers limited UV absorption (estimated SPF 2–4 at peak pigmentation), but it does not prevent UV-induced DNA damage — the primary driver of photocarcinogenesis. The peptide was initially researched as a melanoma prevention strategy, but clinical development was discontinued. Users still require sunscreen and UV-protective behaviour; artificially elevated melanin does not replace photoprotection.

The most common side effect is nausea, occurring in 30–40% of users within 30–60 minutes post-injection due to MC4R activation in the hypothalamus. Spontaneous erections in males and facial flushing are also documented, peaking 1–2 hours after injection and resolving within 4–6 hours. These effects diminish with repeated dosing as receptor adaptation occurs. Serious adverse events were not reported in Phase I trials, but long-term safety data is limited.

Store unreconstituted Melanotan-2 peptide as lyophilised powder at −20°C. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 30 days. Avoid temperature excursions above 25°C and never freeze reconstituted solution — freeze-thaw cycles irreversibly degrade peptide bonds. Reconstitution must be done under sterile conditions; inject bacteriostatic water slowly down the vial wall to avoid foaming, which denatures the peptide.

Response varies by baseline melanocyte density and constitutive melanin. Lighter skin phototypes (Fitzpatrick I–III) show more dramatic pigmentation changes than darker phototypes (IV–VI), which have higher baseline melanin and may experience receptor desensitisation. Individuals with albinism (complete absence of functional tyrosinase) will not tan regardless of dose because the peptide cannot synthesise melanin without the enzyme substrate.

Melanotan-2 peptide is not FDA-approved for human use and is classified as a research chemical. It is legal to purchase for laboratory research purposes in most jurisdictions, but marketing it for human consumption or cosmetic use violates FDA regulations. Possession and use outside of approved research contexts may carry legal risk depending on local and federal statutes.

Pigmentation persists for 3–4 weeks after the last dose because melanin remains in keratinocytes as they migrate through the epidermis. Epidermal turnover occurs approximately every 28 days, so the tan fades at the same rate as natural skin shedding. Maintenance dosing at 0.25–0.5mg once or twice weekly can sustain pigmentation indefinitely without cumulative receptor desensitisation.

Research-grade Melanotan-2 peptide is synthesised under controlled conditions with third-party HPLC verification to confirm amino-acid sequencing accuracy and purity (typically >98%). Underground sources may not provide certificates of analysis, batch traceability, or sterility testing, increasing risk of contamination, incorrect peptide structure, or underdosing. Purity matters for receptor binding studies and reproducibility.

Yes, but UV exposure is not required for pigmentation and does not accelerate Melanotan-2 peptide’s mechanism — melanogenesis occurs independently of photon-induced DNA damage. Combining MT-2 with UV may produce slightly darker pigmentation due to additive melanin synthesis, but it also compounds photocarcinogenic risk. The peptide’s original research aim was to eliminate UV dependence, not enhance it.